Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
filingDate |
2016-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a90ddccbfbbd398c2fc6dc6703b0977a |
publicationDate |
2018-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2018371092-A1 |
titleOfInvention |
Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody |
abstract |
This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10604575-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10323093-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019112377-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022178319-A1 |
priorityDate |
2015-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |